An update on vaccines for tuberculosis – there is more to it than just waning of BCG efficacy with time

Bibliography

• Wirth T, Hildebrand F, Allix- Buegec C. Origin, spread and demography of the mycobacterium tuberculosis complex. PLoS Pathog 2008;4:e1000160
   PubMed Web of Science ®Google Scholar
• WHO 2011. Global tuberculosis control 2011. Available from: who int/tb/publications/global_report 2011
   Google Scholar
• North RJ, Jung YJ. Immunity to Tuberculosis. Annu Rev Immunol 2004;22:599-623
   PubMed Web of Science ®Google Scholar
• Menzies D, Gardiner G, Farhat M, Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Intl J Tuberc Lung Dis 2008;12:498-505
   PubMed Web of Science ®Google Scholar
• Corbett EL, Watt CJ, Walker N, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21
   PubMed Web of Science ®Google Scholar
• WHO Guidelines 2011. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Available from: who int/hiv/pub/tb/9789241500708 2011
   Google Scholar
• Jackson M, Yamamoto S. Historical background of Mycobacterium bovis BCG. In: Takii T, Maeyama J, Yamamoto S, editors. BCG -vaccine and adjuvant. Japan Anti-Tuberculosis Association; Tokyo: 2011. p. 3-12
   Google Scholar
• Kaufmann S, Gengerbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS, Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:689-702
   Google Scholar
• Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
   PubMed Web of Science ®Google Scholar
• Colditz G, Berkey C, Mosteller F. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995;96:29-35
   PubMed Web of Science ®Google Scholar
• Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Ann Rev Pathol 2012;7:353-84
   PubMed Web of Science ®Google Scholar
• Corbett EL. HIV and tuberculosis: surveillance revisited. Intl J Tuberc Lung Dis 2003;7:709
   PubMed Web of Science ®Google Scholar
• Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nature Rev Immunol 2004;4:55-66
   PubMed Web of Science ®Google Scholar
• Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010;161:1-9
   PubMed Web of Science ®Google Scholar
• Caccamo N, Guggino G, Meraviglia S, Analysis of mycobacterium tuberculosis -specific CD8+ T cells in patients with active tuberculosis and in individuals with latent infection. PLoS One 2009;4:e5528
   PubMed Web of Science ®Google Scholar
• Bruns H, Meinken C, Schauenberg P, Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-77
   PubMed Web of Science ®Google Scholar
• Kagina BM, Abel B, Scriba TJ, Hughes E. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-9
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH, Ellner JJ, Kaufmann SH. Ten challenges for TB biomarkers. Tuberculosis (Edinb) 2012;92:S17-20
   PubMed Web of Science ®Google Scholar
• Berry MP, Graham CM, McNab FW, An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-7
   PubMed Web of Science ®Google Scholar
• Maertzdorf J, Ota M, Repsilber D, Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One 2011;6:e26938
   PubMedGoogle Scholar
• Kunnath-Velayudhan S, Gennaro ML. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery. Clin Microbiol Rev 2011;24:792-805
   PubMed Web of Science ®Google Scholar
• Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 2011;183:696-707
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012;92:S6-S13
   PubMed Web of Science ®Google Scholar
• Stop TB Partnership Working Group on New TB Vaccines. Tuberculosis Vaccine Pipeline-2011. StopTB partnership 2011
   Google Scholar
• Ottenhoff THM, Kaufmann SHE. Vaccines against tuberculosis: where are we and where do we need to go ? PLoS Pathog 2012;8:e1002607
   PubMed Web of Science ®Google Scholar
• Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, PhoP: a missing piece in the intricate puzzle of mycobacterium tuberculosis Virulence. PLoS one 2008;3:e3496
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200-7
   PubMed Web of Science ®Google Scholar
• Mori T. Efficacy of BCG vaccination. In: Takii T, Maeyama J-I, Yamamoto S, editors. BCG- vaccine and aduvant. Japan Anti-Tuberculosis Association; Tokyo: 2011. p. 13-45
   Google Scholar
• Aronson NE, Santosham M, Comstock GW, Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60 year follow-up study. JAMA 2004;291:2086-91
   PubMed Web of Science ®Google Scholar
• Dye C. A booster for tuberculosis vaccines. JAMA 2004;291:2127-8
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005;3:656-65
   PubMed Web of Science ®Google Scholar
• Liu PT, Stenger S, Li H, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3
   PubMed Web of Science ®Google Scholar
• Checkley AM, McShane H. Tuberculosis vaccines: progress and chalenges. Trends Pharm Sci 2011;32:601-6
   PubMed Web of Science ®Google Scholar
• Minassian AM, Satti I, Poulton ID, A human challenge model for mycobacterium tuberculosis using mycobacterium bovis bacille calmette-guerin. J Infect Dis 2012;205:1035-42
   PubMed Web of Science ®Google Scholar
• Kampmann B, Tena GN, Mzazi S, Novel human in vitro system for evaluating antimycobacterial vaccines. Infect Immun 2004;72:6401-7
   PubMed Web of Science ®Google Scholar
• Higbee RG, Byers AM, Dhir V. An immunologic model for rapid vaccine assessment – a clinical trial in a test tube. Altern Lab Anim 2009;37:19-27
   PubMed Web of Science ®Google Scholar
• Sweeney KA, Dao DN, Goldberg MF, A recombinant mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011;17:1261-8
   PubMed Web of Science ®Google Scholar
• Barkan D, Hedhli D, Yan H-G, Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. Infect Immun 2012;80:1958-68
   PubMed Web of Science ®Google Scholar
• Dao DN, Sweeney K, Hsu T, Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog 2008;4:e1000081
   PubMed Web of Science ®Google Scholar
• Vander Beken S, Dulayymi J, Naessens Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur J Immunol 2011;41:450-60
   PubMed Web of Science ®Google Scholar
• Warrier T, Tropis M, Werngren J, Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob Agents Chemother 2012;56:1735-43
   PubMed Web of Science ®Google Scholar
• Festjens N, Bogaert P, Batni A, Disruption of the SapM locus in mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. EMBO Mol Med 2011;3:222-34
   PubMed Web of Science ®Google Scholar
• Copenhaver RH, Sepulveda E, Armitige LY, A Mutant of mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun 2004;72:7084-95
   PubMed Web of Science ®Google Scholar
• Saikolappan S, Estrella J, Sasindran SJ, The fbpA/SapM double knock out strain of mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages. PLoS One 2012;7:e36198
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Clagett B, Fitzgerald H, Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012;30:2811-23
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9:776-88
   PubMed Web of Science ®Google Scholar
• Ryan AA, Nambiar JK, Wozniak TM, Antigen load governs the differential priming of CD8+ T cells in response to BCG vaccine or M. tuberculosis. J Immunol 2009;182:7172-7
   PubMed Web of Science ®Google Scholar
• Romano M, Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev Vaccines 2009;8:1237-50
   PubMed Web of Science ®Google Scholar
• Romano M, D'Souza S, Adnet PY, Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from M. tuberculosis increases the survival time of M. bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006;24:3353-64
   PubMed Web of Science ®Google Scholar
• Dou J, Wang Y, Yu F, Protection against mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet 2012;39:183-90
   PubMed Web of Science ®Google Scholar
• Lin MY, Geluk A, Verduyn M, BCG vaccination induces poor responses against DosR regulon encoded antigens that are upregulated in latent Mycobacterium tuberculosis infection. Infect Immun 2007;75:3523-30
   PubMed Web of Science ®Google Scholar
• Roupie V, Romano M, Zhang L, Immunogenicity of eight dormancy (DosR) regulon encoded proteins of mycobacterium tuberculosis in DNA vaccinated and tuberculosis-infected mice. Infect Immun 2007;75:941-9
   PubMed Web of Science ®Google Scholar
• Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422
   PubMed Web of Science ®Google Scholar
• Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb) 2007;87:257-66
   PubMed Web of Science ®Google Scholar
• Hokey DA, Misra A. Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis (Edinb) 2011;91:82-5
   Google Scholar
• Jeyanathan M, Mu J, Kugathasan K, Airway Delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lungs. J Immunol 2008;181:5618-26
   PubMed Web of Science ®Google Scholar
• Gupta A, Gheeta N, Mani J, Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route 51. 2009;77:223-31
   Google Scholar
• Rodriguez A, Tjarnlund A, Ivanyi J, Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 2005;23:2565-72
   PubMed Web of Science ®Google Scholar
• Balu S, Reljic R, Lewis MJ, A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011;186:3113-19
   PubMed Web of Science ®Google Scholar
• Tchillian EZ, Ronan EO, de Lara C, Simultaneous immunization against tuberculosis. PLoS One 2011;6:e27477
   PubMed Web of Science ®Google Scholar
• Schandevyl M. Geschiedenis van de tuberculose. Berichten VRGT (Vlaamse Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding) 2012;21:4-7
   Google Scholar
• McShane H, Pathan AA, Sander C, Recombinant modified vaccinia ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med 2004;10:1240-4
   PubMed Web of Science ®Google Scholar